As there are many studies regarding EGFR-TKI targeting NSCLC, we verified the drug responsiveness of pelitinib relative to LEPRE1 levels in EGFR-expressing human lung cancer-derived A549 cells. This evidence concerns the gene P3H1 and lung carcinoma.